Judith R Kelsen1,2, Maire A Conrad1,2, Noor Dawany3, Trusha Patel1,2, Rawan Shraim1, Audrey Merz1, Kelly Maurer4, Kathleen E Sullivan2,4, Marcella Devoto2,5,6. 1. Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia. 2. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania. 3. Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia. 4. Division of Immunology and Allergy, The Children's Hospital of Philadelphia. 5. Division of Human Genetics, The Children's Hospital of Philadelphia. 6. Department of Translational and Precision Medicine, University Sapienza, Rome, Italy.
Abstract
BACKGROUND: Insight into the pathogenesis of very early onset-inflammatory bowel disease (VEO-IBD) has expanded through the identification of causative monogenic defects detected in a subset of patients. However, the clinical course of this population remains uncertain. The study objective is to determine whether VEO-IBD is associated with more severe disease, defined as increased surgical intervention and growth failure, than older pediatric IBD. Secondary outcomes included therapeutic response and hospitalizations. METHODS: Subjects with IBD diagnosed younger than 6 years old (VEO-IBD) were compared with children diagnosed 6 to 10 (intermediate-onset) and older than 10 years of age (older-onset IBD). Metadata obtained from the medical record included age of onset, disease phenotype and location, surgeries, medical therapy, and comorbid conditions. Length of follow-up was at least 1 year from diagnosis. RESULTS: There were 229, 221, and 521 subjects with VEO, intermediate-onset, and older-onset IBD, respectively. Very early onset-inflammatory bowel disease subjects underwent more diverting ileostomies (P < 0.001) and colectomies (P < 0.001) than the older children. There was less improvement in weight- and height-for-age Z scores during the follow-up period in subjects with VEO-IBD. Additionally, subjects with VEO-IBD had higher rates of medication failure at 1 year and were more frequently readmitted to the hospital. Targeted therapy was successfully used almost exclusively in VEO-IBD. CONCLUSION: Patients with VEO-IBD can have a more severe disease course with increased surgical interventions and poor growth as compared with older-onset IBD patients. Further, VEO-IBD patients are more likely to be refractory to conventional therapies. Strategies using targeted therapy in these children can improve outcome and, in some cases, be curative.
BACKGROUND: Insight into the pathogenesis of very early onset-inflammatory bowel disease (VEO-IBD) has expanded through the identification of causative monogenic defects detected in a subset of patients. However, the clinical course of this population remains uncertain. The study objective is to determine whether VEO-IBD is associated with more severe disease, defined as increased surgical intervention and growth failure, than older pediatric IBD. Secondary outcomes included therapeutic response and hospitalizations. METHODS: Subjects with IBD diagnosed younger than 6 years old (VEO-IBD) were compared with children diagnosed 6 to 10 (intermediate-onset) and older than 10 years of age (older-onset IBD). Metadata obtained from the medical record included age of onset, disease phenotype and location, surgeries, medical therapy, and comorbid conditions. Length of follow-up was at least 1 year from diagnosis. RESULTS: There were 229, 221, and 521 subjects with VEO, intermediate-onset, and older-onset IBD, respectively. Very early onset-inflammatory bowel disease subjects underwent more diverting ileostomies (P < 0.001) and colectomies (P < 0.001) than the older children. There was less improvement in weight- and height-for-age Z scores during the follow-up period in subjects with VEO-IBD. Additionally, subjects with VEO-IBD had higher rates of medication failure at 1 year and were more frequently readmitted to the hospital. Targeted therapy was successfully used almost exclusively in VEO-IBD. CONCLUSION:Patients with VEO-IBD can have a more severe disease course with increased surgical interventions and poor growth as compared with older-onset IBD patients. Further, VEO-IBD patients are more likely to be refractory to conventional therapies. Strategies using targeted therapy in these children can improve outcome and, in some cases, be curative.
Authors: Eric I Benchimol; David R Mack; Geoffrey C Nguyen; Scott B Snapper; Wenbin Li; Nassim Mojaverian; Pauline Quach; Aleixo M Muise Journal: Gastroenterology Date: 2014-06-18 Impact factor: 22.682
Authors: Anbezhil Subbarayan; Gloria Colarusso; Stephen M Hughes; Andrew R Gennery; Mary Slatter; Andrew J Cant; Peter D Arkwright Journal: Pediatrics Date: 2011-04-11 Impact factor: 7.124
Authors: Judith R Kelsen; Andrew B Grossman; Helen Pauly-Hubbard; Kernika Gupta; Robert N Baldassano; Petar Mamula Journal: J Pediatr Gastroenterol Nutr Date: 2014-12 Impact factor: 2.839
Authors: Elizabeth A Worthey; Alan N Mayer; Grant D Syverson; Daniel Helbling; Benedetta B Bonacci; Brennan Decker; Jaime M Serpe; Trivikram Dasu; Michael R Tschannen; Regan L Veith; Monica J Basehore; Ulrich Broeckel; Aoy Tomita-Mitchell; Marjorie J Arca; James T Casper; David A Margolis; David P Bick; Martin J Hessner; John M Routes; James W Verbsky; Howard J Jacob; David P Dimmock Journal: Genet Med Date: 2011-03 Impact factor: 8.822
Authors: Jimmy Z Liu; Suzanne van Sommeren; Hailiang Huang; Siew C Ng; Rudi Alberts; Atsushi Takahashi; Stephan Ripke; James C Lee; Luke Jostins; Tejas Shah; Shifteh Abedian; Jae Hee Cheon; Judy Cho; Naser E Dayani; Lude Franke; Yuta Fuyuno; Ailsa Hart; Ramesh C Juyal; Garima Juyal; Won Ho Kim; Andrew P Morris; Hossein Poustchi; William G Newman; Vandana Midha; Timothy R Orchard; Homayon Vahedi; Ajit Sood; Joseph Y Sung; Reza Malekzadeh; Harm-Jan Westra; Keiko Yamazaki; Suk-Kyun Yang; Jeffrey C Barrett; Behrooz Z Alizadeh; Miles Parkes; Thelma Bk; Mark J Daly; Michiaki Kubo; Carl A Anderson; Rinse K Weersma Journal: Nat Genet Date: 2015-07-20 Impact factor: 41.307
Authors: Holm H Uhlig; Tobias Schwerd; Sibylle Koletzko; Neil Shah; Jochen Kammermeier; Abdul Elkadri; Jodie Ouahed; David C Wilson; Simon P Travis; Dan Turner; Christoph Klein; Scott B Snapper; Aleixo M Muise Journal: Gastroenterology Date: 2014-07-21 Impact factor: 33.883
Authors: Judith R Kelsen; Noor Dawany; Alejandro Martinez; Alejuandro Martinez; Christopher M Grochowski; Kelly Maurer; Eric Rappaport; David A Piccoli; Robert N Baldassano; Petar Mamula; Kathleen E Sullivan; Marcella Devoto Journal: BMC Gastroenterol Date: 2015-11-18 Impact factor: 3.067
Authors: Lauren V Collen; David Y Kim; Michael Field; Ibeawuchi Okoroafor; Gwen Saccocia; Sydney Driscoll Whitcomb; Julia Green; Michelle Dao Dong; Jared Barends; Bridget Carey; Madison E Weatherly; Shira Rockowitz; Piotr Sliz; Enju Liu; Alal Eran; Leslie Grushkin-Lerner; Athos Bousvaros; Aleixo M Muise; Christoph Klein; Vanessa Mitsialis; Jodie Ouahed; Scott B Snapper Journal: J Crohns Colitis Date: 2022-09-08 Impact factor: 10.020
Authors: Huda Husain Al-Numan; Rana Mohammed Jan; Najla Bint Saud Al-Saud; Omran M Rashidi; Nuha Mohammad Alrayes; Hadeel A Alsufyani; Abdulrahman Mujalli; Noor Ahmad Shaik; Mahmoud Hisham Mosli; Ramu Elango; Omar I Saadah; Babajan Banaganapalli Journal: Front Pediatr Date: 2022-05-26 Impact factor: 3.569
Authors: Faith D Ihekweazu; Tatiana Fofanova; Ryan Palacios; Avanthi Ajjarapu; Lina Karam; Adam M Vogel; J R Rodriguez; Richard Kellermayer Journal: J Pediatr Surg Date: 2020-02-03 Impact factor: 2.545